诊断时IgA水平预测慢性淋巴细胞白血病感染、治疗时机与生存
该回顾性分析纳入2005至2014年CancerCare Manitoba诊断的660例CLL(72%)、MBL(13%)和SLL(14%)患者,其中511例在诊断3个月内首次检测免疫球蛋白。诊断时IgG和IgA异常是未来免疫球蛋白替代治疗的独立预测因素,而仅IgA异常与较短至首次治疗时间和总生存相关。
要点
- 诊断时IgG和IgA异常是CLL患者未来需免疫球蛋白替代治疗的独立预测因素。
- 仅诊断时IgA异常与较短至首次治疗时间和总生存相关。
- IgA异常显著与高β2微球蛋白(B2M)表达相关,IgG和IgA异常与IGHV1-69、3-21、3-49亚型使用相关。
核心结论
- 诊断时IgG和IgA降低或升高均为CLL感染的独立预后标志物,其中IgA作为疾病进展和生存标志物更为相关。
研究设计与样本
- 对2005至2014年在CancerCare Manitoba诊断的660例CLL(72%)、MBL(13%)和SLL(14%)患者进行回顾性分析;511例在诊断3个月内检测了首次免疫球蛋白水平。
主要发现
- CLL患者中58%、MBL患者中27%、SLL患者中20%出现IgM、IgG或IgA异常(升高或降低)。
- MBL与CLL Rai 0期、SLL与Rai I–II期的免疫球蛋白异常情况相似;CLL中IgG和IgA异常频率随Rai分期进展而增加,而IgM异常频率在各组相似。
- IgA异常显著与高β2微球蛋白(B2M)表达相关;异常IgG和IgA水平与IGHV1-69、3-21、3-49亚型使用相关。
- IgG或IgM升高常与CLL型M带存在相关,而IgA升高时常见寡克隆带。
- 诊断时IgG和IgA异常是未来免疫球蛋白替代治疗的独立预测因素,但仅IgA异常与较短至首次治疗时间和总生存相关。
临床怎么用
- 诊断时检测免疫球蛋白水平(尤其IgA)可能有助于识别感染风险较高、疾病进展较快及生存较差的CLL患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To better understand the relationship between baseline immunoglobulin measurements and subsequent clinical outcomes in chronic lymphocytic leukemia (CLL), we performed a retrospective analysis on 660 patients with CLL (72%), monoclonal B-cell lymphocytosis (MBL) (13%), and small lymphocytic lymphoma (SLL) (14%), diagnosed between 2005 and 2014 at CancerCare Manitoba. Of 511 patients who had their first immunoglobulin level determined within 3 months of diagnosis, abnormal (either increased or decreased) immunoglobulin M (IgM), IgG, and IgA values were observed in 58% of patients with CLL, 27% of patients with MBL, and 20% of patients with SLL. Immunoglobulin deviances were similar for MBL and CLL Rai stage 0 and for SLL and Rai stages I and II; for CLL, IgG and IgA abnormalities occurred with increasing frequency with advancing Rai stage. In contrast, the frequency of IgM abnormalities was similar in all patient groups. IgA abnormalities significantly correlated with high β2-microglobulin (B2M) expression, whereas abnormal IgG and IgA levels were associated with the use of IGHV1-69, 3-21, and 3-49 subtypes. Increases in IgG or IgM were commonly associated with the presence of a CLL-type M-band, whereas oligoclonal bands were frequently observed with increased IgA levels. Although abnormal levels of IgG and IgA at diagnosis were independent predictors for future immunoglobulin replacement, only abnormal IgA levels were associated with shorter time to first treatment and overall survival. These findings indicate that both reduced and elevated levels of IgG and IgA at diagnosis are important and independent prognostic markers for infection in CLL, with IgA being more relevant as a marker of disease progression and survival.
引用
- Ishdorj G, Streu E, Lambert P, et al. IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Adv. 2019. PMID: 31324639. doi:10.1182/bloodadvances.2018026591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。